Fennec Pharmaceuticals Inc.
FRX.TOTSXHealthcare● Active
$12.72
+$0.00(+0.00%)
Market Cap$363537918
P/E Ratio—
52W High$14.24
52W Low$7.59
Fennec Pharmaceuticals Inc. (FRX.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FRX.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
$0.01
Est. -$0.06 · +122.8%
Revenue
$0.02B
Est. $0.02B · +8.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
FRX.TO reports quarterly as a TSX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.49B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.49B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | $0.03 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.06 | $0.01 | +122.8% | $0.02B | $0.02B | +8.6% |
| ▼ Q1 FY2026 | Mar 24, 2026 | $0.06 | -$0.23 | -503.1% | $0.02B | $0.02B | -6.5% |
| ▼ Q4 FY2025 | Nov 13, 2025 | $0.05 | -$0.03 | -166.1% | $0.02B | $0.01B | +18.3% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.12 | -$0.06 | +50.8% | $0.01B | $0.01B | +52.3% |
| ▼ Q1 FY2025 | Mar 10, 2025 | -$0.09 | -$0.10 | -20.2% | $0.01B | $0.01B | +46.1% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.14 | -$0.29 | -104.1% | $0.01B | $0.01B | +18.2% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -$0.03 | -$0.28 | -728.8% | $0.01B | $0.02B | -34.5% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
$0.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
$0.01
EPS Est.
-$0.06
EPS Surpr.
+122.8%
Revenue
$0.02B
Q1 FY2026
Mar 24, 2026Miss
EPS Actual
-$0.23
EPS Est.
$0.06
EPS Surpr.
-503.1%
Revenue
$0.02B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.03
EPS Est.
$0.05
EPS Surpr.
-166.1%
Revenue
$0.02B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.12
EPS Surpr.
+50.8%
Revenue
$0.01B
Q1 FY2025
Mar 10, 2025Miss
EPS Actual
-$0.10
EPS Est.
-$0.09
EPS Surpr.
-20.2%
Revenue
$0.01B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.29
EPS Est.
-$0.14
EPS Surpr.
-104.1%
Revenue
$0.01B
Q3 FY2024
Aug 13, 2024Miss
EPS Actual
-$0.28
EPS Est.
-$0.03
EPS Surpr.
-728.8%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.35 | $0.38 | $0.42 | 2 |
| Q3 FY2028 | $0.31 | $0.33 | $0.36 | 2 |
| Q2 FY2028 | $0.20 | $0.21 | $0.23 | 2 |
| Q1 FY2028 | $0.16 | $0.17 | $0.19 | 2 |
| Q4 FY2027 | $0.27 | $0.29 | $0.32 | 1 |
| Q3 FY2027 | $0.23 | $0.24 | $0.27 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +122.8% | $9.28 | $12.65 | +36.31% |
| ▼ Q1 FY2026 | Mar 24, 2026 | -503.1% | $10.15 | $8.26 | -18.62% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -166.1% | $10.98 | $10.98 | +0.00% |
| ▲ Q2 FY2025 | May 13, 2025 | +50.8% | $8.66 | $8.66 | +0.00% |
| ▼ Q1 FY2025 | Mar 10, 2025 | -20.2% | $9.82 | $8.81 | -10.29% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -104.1% | $6.86 | $6.08 | -11.37% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -728.8% | $8.62 | $8.16 | -5.34% |
| ▲ Q2 FY2024 | May 14, 2024 | +818.6% | $13.72 | $10.02 | -26.97% |
Q2 FY2026+36.31%
Report Date
May 14, 2026
EPS Beat/Miss
+122.8%
Price Before
$9.28
Price After
$12.65
Q1 FY2026-18.62%
Report Date
Mar 24, 2026
EPS Beat/Miss
-503.1%
Price Before
$10.15
Price After
$8.26
Q4 FY2025+0.00%
Report Date
Nov 13, 2025
EPS Beat/Miss
-166.1%
Price Before
$10.98
Price After
$10.98
Q2 FY2025+0.00%
Report Date
May 13, 2025
EPS Beat/Miss
+50.8%
Price Before
$8.66
Price After
$8.66
Q1 FY2025-10.29%
Report Date
Mar 10, 2025
EPS Beat/Miss
-20.2%
Price Before
$9.82
Price After
$8.81
Q4 FY2024-11.37%
Report Date
Nov 7, 2024
EPS Beat/Miss
-104.1%
Price Before
$6.86
Price After
$6.08
Q3 FY2024-5.34%
Report Date
Aug 13, 2024
EPS Beat/Miss
-728.8%
Price Before
$8.62
Price After
$8.16
Q2 FY2024-26.97%
Report Date
May 14, 2024
EPS Beat/Miss
+818.6%
Price Before
$13.72
Price After
$10.02
Avg Beat Reaction+3.11%
Avg Miss Reaction-9.12%
Beat Rate3 / 8 quarters
Largest Move+36.31% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FRX.TO ends December
Fennec Pharmaceuticals Inc. (FRX.TO) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $0.01 — beating the analyst consensus of $-0.06 by +122.8%. The next FRX.TO earnings date is expected around September 1, 2026.
Each quarter, investors track FRX.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FRX.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FRX.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FRX.TO earnings · 5 questionsFennec Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. FRX.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FRX.TO historically reports after market close (AMC).
FRX.TO earnings datewhen is FRX.TO earningsFRX.TO next earnings datewhen does FRX.TO report earningsFRX.TO earnings calendar
▸ Source: FMP · Fennec Pharmaceuticals Inc. SEC filings · US GAAP · Fennec Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026